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Abstract
An online decision aid to support persons having a genetic predisposition to cancer and their partners during reproductive 
decision-making was developed. A two-phase usability test was conducted among 12 couples (N = 22; 2 persons participated 
without their partner) at risk for hereditary cancer and 15 health care providers. Couples and health care providers expressed 
similar suggestions for improvements, and evaluated the modified decision aid as acceptable, easy to use, and comprehensible. 
The final decision aid was pilot tested (N = 16) with paired sample t tests comparing main outcomes (decisional conflict, 
knowledge, realistic expectations regarding the reproductive options and decision self-efficacy) before (T0), immediately (T1) 
and 2 weeks after (T2) use of the decision aid. Pilot testing indicated decreased decisional conflict scores, increased knowl-
edge, and improved realistic expectations regarding the reproductive options, at T1 and T2. No effect was found for couples’ 
decision self-efficacy. The positive findings during usability testing were thus reflected in the pilot study. The decision aid 
will be further evaluated in a nationwide pretest–posttest study to facilitate implementation in the onco-genetic counselling 
setting. Ultimately, it is expected that the decision aid will enable end-users to make an informed decision.
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Introduction
A predisposition for hereditary cancer is usually autosomal 
dominant, implying that there is a 50% risk of transmitting 
the mutation to offspring. Transmission of a predisposi-
tion for hereditary cancer to offspring means passing on 
a generally highly increased risk of developing cancer. 
For the relatively frequent breast cancer gene mutations in 
BRCA1 or BRCA2 this implies risks of 27–57% and 6–40% 
of developing breast respectively ovarian cancer by the age 
of 70 [1, 2]. This knowledge may evoke challenging repro-
ductive decision-making processes among persons having 
a genetic predisposition to cancer and their partners [3–6]. 
Couples with a predisposition for hereditary cancer who 
want a genetically related child can opt for natural concep-
tion without genetic testing, accepting the risk of passing 
on the predisposition for cancer to a child, or they could 
opt for prenatal diagnosis (PND) assuming the intention 
to terminate the pregnancy if the fetus has the mutation 
[7], or for preimplantation genetic diagnosis (PGD), to 
prevent transmission of the mutation to their offspring. 
PGD involves a multi-stage diagnostic process in which 
embryos are examined for the presence of the familial 
mutation before pregnancy is established [7]. Annually 
approximately 60 couples with a predisposition for heredi-
tary cancer start a PGD procedure in the Netherlands [8], 
a number that has been steadily increasing since its intro-
duction 10 years ago. In 2016, a total of 40 couples with 
a predisposition for hereditary breast and ovarian cancer 
(HBOC) started a PGD procedure and seven couples with 
familial adenomatous polyposis (FAP). The uptake of PND 
for hereditary cancer is relatively low (< 2%) with up till 
2013 only a total of six couples with HBOC performed 
PND (< 0.2%) and a total of six couples with FAP (1.6%) 
[9]. Although awareness of PGD (66%) and PND (61%) 
are similar, the acceptability of PGD (80%) is notably 
higher compared to PND (26%) [10].
The decision regarding which reproductive option to 
choose is highly preference-sensitive. Research has shown 
that persons having a genetic predisposition to cancer and 
their partners may experience the reproductive decision-
making process as complex [6, 11–13]. A recent study 
among couples with HBOC, showed that 43% experienced 
reproductive decision-making as (very) difficult [13]. Feel-
ings of uncertainty and guilt may be experienced, par-
ticularly among couples who opt for natural conception 
without genetic testing [5]. In deliberating the reproduc-
tive options, couples consider personal values and (dis)
advantages of all options, which can be categorized into 
physical (e.g. physical burden of IVF treatment necessary 
for PGD), psychological (e.g. loss of romance regarding 
pregnancy), social (e.g. eliminate mutation in family line), 
ethical (e.g. moral duty to protect the child) and practical 
considerations (e.g. frequent hospital appointments) [5].
The decision regarding which reproductive option to 
pursue should ideally involve an informed decision-making 
process by an educated and empowered couple. In order to 
promote informed decision-making, decisional support strat-
egies can be effective. Compared to usual care interventions, 
decision aids have been found to improve people’s knowl-
edge regarding their options, reduce decisional conflict, 
and decrease the proportion of people remaining undecided 
[13–16]. Incorporating a patient decision aid in reproductive 
counselling can therefore be helpful in supporting persons 
having a genetic predisposition to cancer and their partners 
in making their reproductive decision [5, 17].
The present report is part of a project on the development 
and implementation of an online decision aid. Firstly, we 
conducted a needs assessment study regarding the prefer-
ences and needs of couples and health care providers regard-
ing the decision aid [18]. We integrated the results of the 
needs assessment study with knowledge on reproductive 
decisional motives and considerations and designed a con-
cept version of the decision aid [18]. Its user friendliness, 
strengths and limitations were assessed during usability test-
ing and some modifications were made. Subsequently, the 
final decision aid was pilot tested. We report on the results 
of the usability testing and the preliminary results regarding 
the effectiveness of the decision aid, generates during beta 
testing (i.e. end-user testing) by means of a pilot study [19].
Methods
Developmental process and content of the decision 
aid
The decision aid was developed according to the Interna-
tional Patient Decision Aids Standards [20] in collaboration 
with a steering group including health care providers (e.g. 
clinical geneticists, and social workers), experts in health 
communication and medical decision-making, psycholo-
gists and persons having a genetic predisposition to cancer 
and their partners who are planning to have children. Our 
needs assessment study showed many similarities between 
the expressed preferences and needs of both couples and 
health care providers concerning the content, barriers and 
facilitating factors regarding the use of the decision aid, and 
its implementation [18]. The prototype of the decision aid 
contained:
1. Information about the risk of transmitting the mutation 
to offspring.
2. Information about couples’ options to have genetically 
related child(ren) (natural conception without genetic 
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testing, PND and PGD) with the aim to increase knowl-
edge. In the needs assessment study, participants agreed 
upon natural conception without genetic testing, PND 
and PGD as main reproductive options to be included 
in the decision aid [18]. Adoption and use of donor 
gametes are mentioned in the decision aid to make cou-
ples aware of the existence of these options. However, 
as most couples pursue their wish to have genetically 
related child(ren) [21], these options were not included 
further.
3. Probabilities of different outcomes and the burden of the 
treatment of reproductive options (e.g. risk of miscar-
riage after PND, likelihood of pregnancy with PGD) 
to increase participants’ accuracy of risk comprehen-
sion. Based on current recommendations [22] and the 
preferences of end-users, probabilities were presented 
in multiple suitable formats using text and videos (e.g. 
verbal, and population diagrams).
4. A summary table of important features of each reproduc-
tive option to facilitate comparison.
5. Values clarification exercises (VCE) [23]. Participants 
were presented with 18 statements representing values 
and motives considered important for reproductive deci-
sion-making [5]. Participants were asked to rate personal 
agreement of each statement on a scale from 1 (disagree) 
to 6 (agree). By linking login codes, an automated com-
bined overview of both partners’ input could be gener-
ated to facilitate communication about agreements and 
possible discrepancies.
6. A question prompt sheet, providing examples of ques-
tions and requests for additional information and space 
for own questions, to facilitate discussion with health 
professionals and others.
7. Information regarding the scientific resources used 
to underpin the decision aid content, information on 
the development team (including ‘conflicts of interest 
COI’), funding resources and contact information.
Usability testing
Minor textual revisions were made after review of the pro-
totype decision aid by the steering group. Subsequently, a 
two-phase usability test with couples and health care provid-
ers was conducted. After the first phase the decision aid was 
adapted based on provided feedback. To make final modifi-
cations, a second usability phase was conducted.
Participants and recruitment
Dutch couples who consider PGD are referred to the 
Clinical Genetics Department of the Maastricht Univer-
sity Medical Centre (Maastricht UMC+) for an once only 
informative consultation. The couples are registered in a 
database. Eligible participants for the usability test were 
selected from this database. Couples were eligible for par-
ticipation if one partner had a confirmed mutation for a 
hereditary cancer syndrome for which PND and PGD are 
available in the Netherlands, if they had made a repro-
ductive decision (as indicated in medical records), if both 
partners were 18 years or older, had sufficient knowledge 
of the Dutch language, and if they had ample experience 
with the use of computers and the Internet. Although par-
ticipation of both partners was encouraged, participation 
of one partner (regardless of being carrier) was allowed. 
Couples who provided written informed consent for par-
ticipation were contacted by telephone to schedule an 
appointment at the hospital, or, if preferred, at the cou-
ple’s home.
Furthermore, two representatives of each of the nine 
Clinical Genetics Departments in the Netherlands, who were 
directly involved in the counseling and care of end-users 
(e.g. clinical geneticists and gynecological oncologists) were 
invited to participate (N = 18). Appointments were sched-
uled at convenient workplaces.
Procedures
Usability testing was conducted using a mixed methods 
design (i.e. qualitative and quantitative) in between March 
and June 2016. First, couples and health care providers were 
asked to fill in a brief questionnaire. Age, gender, educational 
level, carrier status, type of cancer, and experience with the 
use of computers and the Internet were assessed for couples. 
Health care providers completed questions concerning their 
professional perspectives regarding the feasibility of imple-
menting the decision aid. Subsequently, participants were 
invited to an online ‘cognitive walkthrough’ of the decision 
aid in presence of the researcher. They were asked to think 
aloud and to express freely their opinion regarding its con-
tent, functionalities, format and layout [24]. The research-
ers occasionally asked predetermined questions. ‘Thinking 
aloud’ sessions were followed by interviews. The content of 
the semi-structured topic guides for the interviews focused 
on the perceived comprehensibility, usability, efficiency and 
acceptability of the decision aid and were largely similar 
for the couples and the health care providers. At the end of 
the interviews, couples were asked to evaluate the decision 
aid with regard to content, lay-out and usability on a scale 
of 1–10 and to complete the System Usability Scale (SUS) 
for the subjective assessment of usability [25–27]. Couples 
received 15 euros in vouchers and their travel expenses were 
reimbursed. Health care providers were asked to evaluate the 
decision aid in terms of quality, completeness, lay-out and 
usability on a scale of 1–10 with higher scores indicating 
better usability.
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Data analysis
Qualitative data derived from the audiotaped ‘thinking 
aloud’ sessions and the interviews were transcribed verba-
tim. Open coding (developing categories of information) 
and axial coding (exploring the relationship of categories) 
was performed independently by two researchers (K.R. 
and M.T.) to derive and categorize main issues. Data from 
the demographic questionnaire and SUS were analysed by 
means of descriptive statistics and quantified as mean and 
standard deviation or absolute number and percentage, using 
SPSS version 23.
Pilot study
Participants and recruitment
Health care providers of all Clinical Genetics Departments 
in the Netherlands recruited eligible couples during or after 
oncogenetic consultation. The same inclusion criteria were 
used as for usability testing, except that couples had not yet 
made a reproductive decision. Couples were eligible if they 
expressed the wish to have children within 5 years and have 
not yet made a definitive decision regarding their preferred 
reproductive option. Although participation of both partners 
was encouraged, participation of one partner was allowed.
Procedures and instrumentation
Adaptation of feedback provided during usability testing 
resulted in the final decision aid. It was pilot tested from 
November 2016 to January 2017. Eligible couples were 
provided with an information brochure, to introduce the 
study together with a link to an online registration page. 
After registration, participants received online information 
about the study and an online informed consent form. After 
providing consent, participants were directed to an online 
(baseline) questionnaire (T0) and received a personal login 
code for the decision aid. Duration of visits and page visits 
were monitored. Immediately after use of the decision aid, 
participants were directed to the second online questionnaire 
(T1). Two weeks after baseline, participants were asked by 
e-mail to complete the last questionnaire (T2). Participants 
who did not complete the questionnaire received a reminder 
by e-mail. Questionnaires were completed separately by both 
partners. After completing all questionnaires, participants 
received 15 euros in vouchers.
A demographic questionnaire assessed gender, age, 
educational level, carrier status, type of cancer, and per-
sonal history of cancer at T0. Less than primary, primary 
and lower secondary education was considered as low 
education levels. Upper secondary and post-secondary 
non-tertiary education was considered as middle educa-
tion levels. Tertiary education was considered as a high 
education level. In addition, participants’ reproductive his-
tory was assessed. The primary outcome measure, i.e. par-
ticipants’ level of decisional conflict, was assessed by the 
Decisional Conflict Scale at T0, T1 and T2. The question-
naire contains 16 items, each scored on a 5-point Likert 
scale ranging from 0 (strongly agree) to 4 (strongly disa-
gree). Total scores range from 0 (no decisional conflict) 
to 100 (extremely high decisional conflict) [28]. Partici-
pants’ current knowledge of the three reproductive options 
was assessed by 15 closed-ended questions (true/false/not 
sure) at T0, T1 and T2, see Table 1 [10]. Three questions 
measured participants’ knowledge of natural conception 
without genetic testing (e.g. ‘when opting for natural con-
ception, there is a 50% risk of transmitting the mutation 
to offspring’), five questions measured knowledge of PND 
(e.g. ‘prenatal diagnosis takes place during pregnancy’) 
and seven questions measured knowledge of PGD (e.g. ‘In 
vitro fertilization (IVF) is necessary to perform PGD’). 
One point was provided for each correctly answered ques-
tion, which could lead to a maximum score of 15. Realis-
tic expectations regarding the three reproductive options 
were assessed by three questions at T0, T1 and T2 (i.e. 
“what is the extra risk of miscarriage due to PND?”, “what 
is the chance of pregnancy after one IVF treatment with 
PGD?”, “what is the risk of complications with PGD?”). 
These questions contained 8–11 response options. One 
point was provided for each correctly answered question, 
which could lead to a maximum score of three [29]. Partic-
ipants’ decision self-efficacy was assessed by the Decision 
Self-Efficacy Scale at T0, T1 and T2. The questionnaire 
contains 11 items, each scored on a 5-point Likert scale 
ranging from 0 (not at all confident) to 4 (very confident). 
Total scores range from 0 (extremely low self-efficacy) to 
100 (extremely high self-efficacy) [30].
Data analysis
To test for intra-couple correlation, we compared two 
models for testing the difference in the main outcome 
(decisional conflict); one linear mixed-effects model in 
which clustering within couples was corrected for, and 
one model without correction. Both models yielded simi-
lar results, and a likelihood-ratio test showed that correc-
tion did not lead to a better fit (likelihood ratio = 0.60, 
p = 0.44). Therefore, all participants can be analyzed as 
separate individuals and we chose to report the simpler 
model without correction for clustering and used paired 
sample t tests to compute differences between the first and 
subsequent measurements. P-values of < 0.05 were con-
sidered to indicate statistical significance.
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Compliance with ethical standards
This study was approved by the medical ethics committee of 
Maastricht UMC+ (METC 14-5-089) and registered in the 
Dutch Trial Register (NTR5467). The authors declare that 
they have no conflict of interest. All procedures performed 
in this study were in accordance with the ethical standards 
of the medical ethics committee of Maastricht University 
Medical Centre and have been performed in accordance with 
the ethical standards as laid down in the 1964 Declaration 
of Helsinki and its later amendments. Informed consent was 
obtained from all patients included in this study.
Results
Usability testing
Couples’ characteristics
Thirty-nine couples who had reproductive counseling for 
hereditary cancer between 2013 and 2015, were invited 
for participation by mail. Twelve couples provided written 
informed consent (N = 22; 2 persons participated without 
their partner), and participated in usability testing (response 
rate 30.8%). Main reasons for non-participation were a lack 
of time and not wanting to relive the psychological burden 
associated with reproductive decision-making. The mean 
age was 34.5 years for males (SD = 4.5) and 29.9 years 
(SD = 3.7) for females. Most participants were highly edu-
cated (64%), a minority had lower education levels (14%) 
and 23% had an average education level. The types of can-
cer concerned hereditary breast and ovarian cancer (N = 6), 
familial adenomatous polyposis (N = 2), Lynch syndrome 
(N = 3) and multiple endocrine neoplasia (N = 1).
Usability results couples
During the first phase of the usability test, three couples 
and one female participant without partner (N = 7 persons) 
participated. A frequently expressed concern during the 
‘think aloud’ sessions was the amount of scrolling needed 
to read all provided information. Other suggestions mainly 
pertained to textual improvements and adaptations to further 
improve lay-out (e.g. change the order of information and a 
change of colors). The average duration of the sessions was 
71 min (range 60–80). Seven couples and one female par-
ticipant without partner (N = 15 persons) participated in the 
second phase of usability testing to make final modifications. 
In general, couples appreciated the lay-out and stated that 
information in the decision aid was clear and comprehensi-
ble. Most couples indicated that they would have used the 
decision aid, if it had been available at the time of reproduc-
tive decision-making, and stated that all functions included 
Table 1  Knowledge of the three reproductive options (pilot study)
Total score range 0–15
No. Item
Natural conception without genetic testing
1  When opting for natural conception, there is a 50% risk of transmitting the mutation to offspring (T)
2  When opting for natural conception, besides standard procedures, there will be no extra examinations per-
formed during pregnancy (T)
3  When opting for natural conception, during delivery it is already clear whether your child has the mutation 
(F)
Prenatal diagnosis
4  Prenatal diagnosis takes place during pregnancy (T)
5  When opting for prenatal diagnosis, you and your partner can naturally conceive (T)
6  Results of prenatal diagnosis will always follow within 1 week (F)
7  Prenatal diagnosis is possible from 6 weeks of pregnancy upon (F)
8  Prenatal diagnosis is possible in most of the medical centers in the Netherlands (T)
PGD
9  In vitro fertilization (IVF) is necessary to perform PGD (T)
10  PGD is possible in every hospital in the Netherlands (F)
11  For PGD, cooperation of family members is a prerequisite (T)
12  Hormone-use by the woman is necessary for a PGD treatment (T)
13  PGD takes place before the woman is pregnant (T)
14  A PGD treatment takes at least 6 months (T)
15  In the Netherlands, a woman’s maximum age for PGD is 45 (F)
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in the decision aid were well integrated (Table 2). Couples 
generally agreed that the decision aid was not unnecessarily 
complex (Table 2). With a mean SUS score (range 0–100) 
of 91.33 (SD = 7.61), the decision aid’s usability was con-
sidered high. Couples graded the decision aid on a scale of 
1–10 with a mean of 8.5 (SD = 0.5) for the content, a mean 
of 8.3 (SD = 0.8) for lay-out and a mean of 8.0 (SD = 0.9) 
for usability.
Health care providers’ characteristics
Fifteen health care providers participated (response rate 
83.3%) in the ‘think aloud’ sessions and individual inter-
views (1 male and 14 females). The mean age for males 
was 61 years and mean age for females was 43.5 years 
(SD = 6.7). These health care providers were clinical genet-
icists (N = 6), gynecological oncologists (N = 3), genetic 
counselors (N = 2), social worker (N = 1), medical oncolo-
gists (N = 2) and an ophthalmologist (N = 1; involved in the 
care and counseling of persons with a predisposition for 
retinoblastoma and their partners). The majority had more 
than 5 years of work experience in the area of oncogenetic 
counseling and 80% had no or limited experience with the 
use of decision aids.
Usability results health care providers
The average duration of the sessions was 59 min (range 
15–80). Similar to couples, health care providers highly 
appreciated the lay-out of the decision aid, although dur-
ing ‘think aloud’ sessions the use of more subtle colors 
was suggested. Several textual suggestions (e.g. avoidance 
of medical/technical terms) and suggestions to change the 
order of information were provided. The different forms 
of information provision (e.g. written and video-based) 
and the (VCE) were appreciated. To promote (continued) 
implementation, it was suggested to include a link to the 
decision aid in the standard report couples receive after 
consultation. The format of the final decision aid was con-
sidered as acceptable, easy to use and comprehensible. 
Health care providers graded the decision aid on a scale 
of 1–10 with a mean score of 8.2 (SD = 0.5) for quality, 
a mean of 8.5 (SD = 0.5) for completeness, a mean of 7.9 
(SD = 0.4) for lay-out and a mean of 7.3 (SD = 0.7) for 
usability. The moderate mean usability score of 7.3 was 
likely due to the order in which information was presented 
in the decision aid. Changes were made to the decision aid 
based on feedback provided.
Pilot study
Participants’ characteristics
Eight couples (N = 16) participated in the pilot study. A 
response rate could not be estimated because the exact 
number of patients invited by each Clinical Genetics 
Department is unknown due to the large number of coun-
selors recruiting. Table 3 shows an overview of the sample 
characteristics. Participants’ average age was 32.4 years 
for males (SD = 4.6) and 29.1 years (SD = 4.3) for females. 
None of the participants had a low education level. Of 
the participants, 68.8% already had a preferred option in 
mind at baseline, 31.2% did not. None of the participants 
changed their mind from T0–T1 and from T0–T2. The 
mean time spent using the decision aid was 27 min (range 
2–104 min) and participants viewed on average 20 out 
of 36 pages. 69% viewed at least 25 pages with pages on 
contact information and disclaimer being the least viewed.
Table 2  System usability scale 
results (usability study)
Total score range 0–100; higher scores indicate higher perceived usability
DA decision aid
No. Item N = 15
Mean (SD)
1 I think that I would like to use the DA frequently 3.07 (1.16)
2 I found the DA unnecessarily complex 0.20 (0.78)
3 I thought the DA was easy to use 3.53 (0.74)
4 I think that I would need technical support to be able to use the DA 0.00 (0.00)
5 I found the various functions included in the DA well integrated 3.47 (0.64)
6 I thought there was too much inconsistency in the DA 0.40 (1.06)
7 I would imagine that people would learn to use the DA very quickly 3.53 (0.52)
8 I found the DA very cumbersome to use 0.07 (0.26)
9 I felt very confident using the DA 3.73 (0.46)
10 I needed to learn a lot before I could get going with the DA 0.13 (0.35)
Total score 91.33 (7.61)
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Preliminary effects of decision aid
All 16 participants completed T0 and T1 and 15 participants 
completed T2. As shown in Table 4, mean decisional con-
flict scores (range 0–100) decreased from a mean of 27.6 
(SD = 19.3) at baseline, to 11.8 (SD = 15.3) at T1 (t = 5.73; 
p < 0.001; ES = 1.73) and 8.3 (SD = 6.4) at T2 (t = 3.37; 
p = 0.01; ES = 1.12). The mean level of knowledge (range 
0–15) increased from 8.2 (SD = 3.5) at baseline, to 12.4 
(SD = 3.7) at T1 (t = − 7.73; p < 0.001; ES = − 1.93) and 
12.8 (SD = 2.1) at T2 (t = − 10.05; p < 0.001; ES = − 2.69). 
Further, realistic expectations regarding the three repro-
ductive options (range 0–3) increased from 0.4 (SD = 0.5) 
at baseline, to 1.9 (SD = 1.0) at T1 (t = − 6.45; p < 0.001; 
ES = − 0.75) and 1.3 (SD = 1.0) at T2 (t = − 4.33; p < 0.001; 
ES = − 0.25). Couples’ decision self-efficacy (range 0–100) 
slightly increased but did not significantly change over time 
from 80.4 (SD = 16.9) at baseline, to 81.3 (SD = 16.0) at T1 
(t = − 0.28; p = 0.782; ES = − 0.07) and 83.9 (SD = 19.6) at 
T2 (t = − 0.38; p = 0.708; ES = − 0.10).
Discussion
This study presents the development and preliminary 
evaluation of an online decision aid that aims to support 
persons having a genetic predisposition to cancer and their 
partners during their reproductive decision-making. Previ-
ous studies demonstrated that these couples may experi-
ence the decision-making process as complex [6, 11, 12, 
31]. The decision aid aims to decrease participants’ level 
of decisional conflict, increase participants’ knowledge, 
improve realistic expectations regarding the available 
reproductive options and increase participants’ decision 
self-efficacy. The high mean score on the SUS indicates 
that the decision aid meets the needs of the target popu-
lation. During usability testing, couples and health care 
providers expressed similar suggestions for improvements. 
Overall the decision aid was evaluated as acceptable, easy 
to use, and comprehensible. The positive findings during 
usability testing were reflected in the preliminary results 
regarding efficacy of the decision aid, indicated by reduc-
tion of couples’ decisional conflict levels, increases in 
knowledge levels and improvement of realistic expecta-
tions regarding available reproductive options. This sug-
gests that with use of the decision aid, informed decision-
making among persons having a genetic predisposition to 
cancer and their partners during reproductive decision-
making may be improved. Despite the complexity of the 
decision, couples’ confidence in their ability to make a 
decision was already high at baseline and did not increase 
as a result of decision aid use, possibly reflecting a ceiling 
effect. This may be explained by the finding that 11 out of 
16 participants already had a preferred reproductive option 
in mind at baseline, indicating that couples had already 
considered the available reproductive options to a certain 
extent. However, although couples overall felt confident 
about making a reproductive decision, baseline knowledge 
levels were relatively low. As a solid knowledge base is 
regarded as a prerequisite for informed decision-making 
[32], this finding further emphasizes the need for informa-
tional support among our sample.
In order to optimize the impact of the decision aid with 
regard to decision self-efficacy, the use of modeling tech-
niques may be considered [33], for instance by means of 
incorporating narrative stories in the decision aid. Previ-
ous research, including a needs assessment regarding the 
current decision aid, indicated that both couples and health 
care providers advocate the provision of narrative stories 
during reproductive decision-making [5, 18]. These per-
sonal stories detail the experiences of couples with repro-
ductive decision-making and are aimed at providing illus-
trative examples of others’ experiences. Narratives can be 
useful in overcoming preconceived beliefs and cognitive 
Table 3  Sample characteristics (pilot study)
Sample characteristics (n = 16) N %
Gender
 Male (M) 8 50.0
 Female (F) 8 50.0
Age (years)
 Male 32.4 (SD = 4.6)
 Female 29.1 (SD = 4.3)
Education
 Middle 7 43.8
 High 9 56.2
Carrier status
 Male 2 12.5
 Female 6 87.5
Syndrome
 Hereditary breast and ovarian cancer 7 (5F/2M) 87.5
 Lynch syndrome 1 (F) 12.5
Have (had) cancer
 Yes 4 25.0
 No 12 75.0
Reproductive history
 Children
  Yes 2 12.5
  No 14 87.5
 Planning to have children
  Currently pregnant 2 12.5
  Planning to have children within 5 years 14 87.5
Preferred reproductive option in mind at T0
 Yes 11 68.8
 No 5 31.2
 K. Reumkens et al.
1 3
biases and integrating narratives into healthcare commu-
nication is increasingly being recommended [34, 35]. Cur-
rently insufficient evidence exists about the effectiveness 
of narrative stories on informed decision-making and how 
to incorporate these stories in decision support tools [36, 
37]. Future research should explore essential elements of 
the content of narrative stories and their effectiveness in 
facilitating decision-making.
A limitation of this study relates to the small sample size 
and selection bias towards higher educated and possibly higher 
health literate users which may limit generalizability of the 
results. Subsequently, the decision aid will be further evaluated 
in a nation-wide effect study to draw more robust conclusions. 
Ultimately, it is expected that the decision aid will enable end-
users to make an informed decision, which may lessen the 
negative psychological impact of decision-making on couples’ 
daily life and wellbeing.
Conclusions
The current findings indicate that the decision aid was 
well received by both couples and health care providers as 
reflected in high usability scores and promising prelimi-
nary efficacy during the pilot study. The decision aid will 
be further evaluated in a nationwide pretest–posttest study.
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Table 4  Overview of main 
outcome measures (pilot study) Questionnaire (N = 16) Means (SD) Paired samples t-test
T0 T1 T2 T0–T1 T0–T2
T p T p
Decisional conflict
 Total score (0–100) 27.6
(19.3)
11.8
(15.3)
8.3
(6.4)
5.73 < 0.001 3.37 0.010
 Uncertainty 43.8
(28.5)
27.6
(30.4)
29.2
(27.7)
3.67 0.002 2.19 0.047
 Informed 40.6
(22.5)
17.7
(18.5)
11.3
(13.7)
5.21 < 0.001 5.97 < 0.001
 Values clarity 30.2
(26.2)
19.3
(21.9)
11.9
(15.6)
2.78 0.014 3.54 0.004
 Support 24.0
(16.6)
17.7
(18.0)
13.7
(14.1)
1.60 0.131 2.65 0.020
 Effective decision 17.6
(15.0)
8.0
(15.3)
5.6
(11.5)
4.54 < 0.001 1.71 0.126
Knowledge
 Total score (0–15) 8.2
(3.5)
12.4
(3.7)
12.8
(2.1)
− 7.73 <0.001 − 10.05 < 0.001
 Natural conception (0–3) 2.0
(1.0)
2.3
(0.9)
2.5
(0.9)
− 1.78 0.096 − 2.45 0.028
 PND (0–5) 1.8
(1.7)
3.9
(1.4)
4.5
(2.0)
− 5.33 < 0.001 − 3.96 < 0.001
 PGD (0–7) 4.4
(1.8)
6.1
(1.9)
6.4
(0.9)
− 5.65 < 0.001 − 3.67 0.003
Realistic expectations (0–3) 0.4
(0.5)
1.9
(1.0)
1.3
(1.0)
− 6.45 < 0.001 − 4.33 < 0.001
Decision self-efficacy (0–100) 80.4
(16.9)
81.3
(16.0)
83.9
(19.6)
− 0.28 0.782 − 0.38 0.708
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